Fig. 2

Mean percentage of patients with: a ≥50% and b ≥75% reduction in monthly migraine headache days (total population)^#; c ≥30%, d ≥50%, and e ≥75% reduction in monthly migraine headache days in patients with CM^#; and f ≥50% reduction in monthly migraine headache days in patients with EM^#. Note: Only 30% response for patients with chronic migraine was pre-specified and was included in this analysis. ^# Patients who had failed 3–4 preventive medication categories due to inadequate efficacy (after at least 2 months at maximum tolerated dose), or safety or tolerability reasons within the last 10 years. ***P ≤ .001, **P ≤ 0.01, *P ≤ .05 versus placebo. CI: confidence interval; CM: chronic migraine; EM: episodic migraine; GMB: galcanezumab; LS: least squares; n: number of patients with non-missing baseline value and at least one post-baseline value; OR: odds ratio; SE: standard error